International Presence

New Technologies/ view all

  • Transgenic animals to produce therapeutic proteins

    Biosidus has concluded is working on novel technologies for high-yield and cost-effective production of recombinant proteins for pharmaceutical applications.

    More
  • Gene Therapy

    Angiogenesis and muscle regeneration using the vascular endothelial growth factor.
    Vascular endothelial growth factor (VEGF) is a protein that stimulates the growth of blood vessels.

    More
  • Biodiversity

    White Genome Project
    Yet another groundbreaking initiative for Biosidus is the White Genome Project, which aims to isolate, identify and characterize Antarctic bacterial strains for further sequencing of the complete genome.

    More

Biosidus in the world | internacional Presence

With more than two decades of expertise in the manufacture and distribution of high quality biosimilar products in emerging market countries, a strong portfolio and pipeline of products, significant development and manufacturing capabilities and an established network of distribution partners, we believe we are well positioned to take advantage of opportunities for growth in the global biosimilar therapeutics market.

Since the launch of our first product in 1990, we have expanded our commercial activity into the territories of Africa, Middle East, South Eastern Asia, Eastern Europe and Latin America through a vast network of licensees.

The company’s goal and next step in its commercial strategy is to enter highly regulated markets such as USA, EU and Japan.